PaxMedica (NASDAQ:PXMD) Shares Up 4%

Shares of PaxMedica, Inc. (NASDAQ:PXMDGet Rating) shot up 4% during trading on Thursday . The stock traded as high as $2.20 and last traded at $2.09. 478,689 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 1,768,271 shares. The stock had previously closed at $2.01.

PaxMedica Trading Up 4.0 %

The stock has a 50 day moving average of $2.22.

PaxMedica (NASDAQ:PXMDGet Rating) last released its earnings results on Friday, September 30th. The company reported ($0.14) EPS for the quarter.

Hedge Funds Weigh In On PaxMedica

An institutional investor recently bought a new position in PaxMedica stock. Jane Street Group LLC purchased a new stake in PaxMedica, Inc. (NASDAQ:PXMDGet Rating) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 18,025 shares of the company’s stock, valued at approximately $43,000. Jane Street Group LLC owned about 0.15% of PaxMedica as of its most recent SEC filing.

PaxMedica Company Profile

(Get Rating)

PaxMedica, Inc, a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis.

Recommended Stories

Receive News & Ratings for PaxMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PaxMedica and related companies with MarketBeat.com's FREE daily email newsletter.